10-Q: BioRestorative Therapies Reports Widening Losses, Going Concern Doubt

BioRestorative Therapies, Inc. reported a significant increase in net loss and cash burn for Q3 and the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended September 30, 2025, significantly increased to $3.04 million from $1.09 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, widened to $11.03 million from $7.34 million in the comparable prior year period.
• Total revenues for the three months decreased to $11,800 from $233,600, primarily due to a drop in cosmetic product sales.
• Total revenues for the nine months slightly decreased to $340,100 from $357,700.
• Research and development expenses surged by 78.5% for the three months and 49.2% for the nine months, driven by Phase 2 clinical trial costs and lab supplies.
• Cash used in operating activities increased to $8.37 million for the nine months ended September 30, 2025, compared to $5.88 million in the prior year.
• Working capital decreased significantly to $1.27 million as of September 30, 2025, from $7.40 million at December 31, 2024.
• The company's current funds are insufficient to complete development activities or achieve profitable operations, leading to a 'going concern' warning.
• Subsequent to the reporting period, the company closed a registered direct offering and private placement on October 8, 2025, raising approximately $1.1 million in gross proceeds.

Sentiment

Score: 2

Explanation: The company's financial performance is significantly negative, marked by widening losses, increased cash burn, and a substantial decrease in working capital and equity. The explicit 'going concern' warning and the stated insufficiency of current funds for long-term operations indicate a highly precarious financial position, despite recent capital raises.

Positives

• The Data Safety Monitoring Board unanimously recommended continuing the Phase 2 clinical trial for BRTX-100 without any changes in June 2023.
• Royalty revenue increased to $11,800 for the three months ended September 30, 2025, from $2,900 in the prior year, driven by an increase in disc procedures.
• The company successfully raised approximately $1.1 million in gross proceeds through a registered direct offering and private placement in October 2025, providing additional capital.
• A gain on the change in fair value of warrant liabilities of $612,064 was recognized for the three months ended September 30, 2025, and $552,536 for the nine months ended September 30, 2025.

Negatives

• Net loss for the three months ended September 30, 2025, increased significantly to $3.04 million from $1.09 million in the prior year.
• Net loss for the nine months ended September 30, 2025, increased to $11.03 million from $7.34 million in the prior year.
• Total revenues for the three months ended September 30, 2025, decreased substantially to $11,800 from $233,600, primarily due to a decrease in cosmetic product sales.
• Cash used in operating activities increased to $8.37 million for the nine months ended September 30, 2025, from $5.88 million in the prior year, indicating higher cash burn.
• Working capital decreased by $6.12 million to $1.27 million as of September 30, 2025, from $7.40 million at December 31, 2024.
• Investments held in marketable securities decreased significantly to $3.89 million as of September 30, 2025, from $10.18 million at December 31, 2024.
• Total stockholders' equity decreased substantially to $2.21 million as of September 30, 2025, from $8.53 million at December 31, 2024.
• Interest income decreased for both the three and nine-month periods due to a lower average balance of marketable securities.
• Other income for the nine months ended September 30, 2025, was significantly lower at $3,336 compared to $150,498 in the prior year, which included a one-time payment.

Risks

• The company's ability to obtain financing needed to complete clinical trials and implement its business plan is uncertain.
• There is substantial doubt about the company's ability to continue as a going concern for at least twelve months after the issuance date of the financial statements.
• Current funds are not sufficient to fully complete development activities or attain profitable operations, potentially leading to curtailment of activities or liquidation.
• The company faces risks in successfully developing and commercializing BRTX-100, the ThermoStem Program, and the commercial biocosmeceuticals platform.
• Challenges exist in protecting proprietary rights and achieving and sustaining profitability of existing business lines.
• The company needs to attract and retain world-class research and development talent and expand its management team.
• Estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing may be inaccurate.
• Business interruptions from geopolitical actions, war, terrorism, or disease outbreaks pose risks.
• The company's ability to attract and retain customers is a risk factor.
• Navigating the increasingly complex therapeutic regulatory environment is a challenge.
• Risks are associated with successfully engaging in any new business lines.
• Material weaknesses in internal control over financial reporting persist, including lack of adherence to formal policies, inadequate risk assessment, and ineffective controls over financial reporting and warrant accounting.

Future Outlook

The company anticipates continued net losses and negative cash flows from operations as it executes its development plans for 2025 and beyond. Current funds are explicitly stated as insufficient to fully complete development activities or attain profitable operations, necessitating additional financing. Failure to secure timely financing could lead to curtailment of development, marketing, and promotional activities, or even discontinuation of operations.

Management Comments

• Management believes that the expectations reflected in the forward-looking statements are reasonable, but cannot guarantee future results, levels of activity or performance.
• Management is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies contributing to the material weaknesses are remediated as soon as possible.

Industry Context

BioRestorative Therapies operates in the highly capital-intensive and regulated biotechnology and regenerative medicine sectors, focusing on adult stem cell therapies for disc/spine disorders (brtxDISC) and metabolic disorders (ThermoStem Program). The company also has a nascent biologics-based cosmetic products business. The significant R&D expenses are typical for a company in the clinical trial phase, but the substantial increase in net loss and cash burn, coupled with a 'going concern' warning, highlights the inherent financial challenges and risks in bringing novel therapies to market. The cosmetic product sales, while a new revenue stream, experienced a significant quarterly decline, indicating volatility in this segment.

Corporate Governance

Related Party Transactions

• Issuance of 63,525 shares of common stock to Auctus Fund, LLC on March 20, 2025, in partial satisfaction of shares held in abeyance.
• Issuance of 220,000 shares of common stock to Auctus Fund, LLC on October 27, 2025 (subsequent event), in partial satisfaction of shares held in abeyance.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity financings due to the company's substantial cash burn and 'going concern' issues.
• Shareholders are exposed to increased financial risk due to widening net losses and a significant decrease in working capital and total equity.
• Employees and management may face uncertainty regarding job security and compensation if the company is unable to secure sufficient additional financing.
• Customers of the cosmetic product line may experience inconsistent product availability due to 'timing of orders' affecting revenue recognition.
• Creditors face increased risk due to the company's 'going concern' warning and reliance on future financing.

Next Steps

• Continue Phase 2 clinical trial for BRTX-100 for chronic lower back pain.
• Continue research and development efforts for the ThermoStem Program and biocosmeceuticals platform.
• Seek additional equity and debt financing to fund ongoing losses and development plans.
• Implement remediation measures for identified material weaknesses in internal control over financial reporting, including enhanced oversight, external consulting, and documentation of procedures.
• Potentially repurchase up to $2,000,000 of common stock through June 16, 2026, under the authorized program (no repurchases made as of Sep 30, 2025).

Key Dates

Recommendation

The filing presents a highly concerning financial picture, with a substantial increase in net losses and cash burn from operations. The explicit 'going concern' warning, coupled with a significant decline in working capital and total equity, indicates severe liquidity challenges. While recent capital raises provide some short-term relief, the company explicitly states these funds are insufficient for long-term development and profitability. The persistent material weaknesses in internal controls further compound the risk. For a seasoned investor, these factors point to a high probability of further dilution, continued operational losses, and significant downside risk, making a 'strong sell' recommendation appropriate.

Keywords

BioRestorative Therapies, BRTX, 10-Q, SEC filing, biotechnology, stem cells, BRTX-100, Disc/Spine Program, ThermoStem Program, regenerative medicine, clinical trials, going concern, financial results, net loss, cash flow, capital raise, warrant liabilities, corporate governance, internal controls, cosmetic products